[HTML][HTML] The complement system in COVID-19: friend and foe?
Coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2) has resulted in a global pandemic and a disruptive …
syndrome coronavirus-2 (SARS-CoV-2) has resulted in a global pandemic and a disruptive …
PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the Bad Berka experience since 2013
HR Kulkarni, A Singh, C Schuchardt… - Journal of Nuclear …, 2016 - Soc Nuclear Med
… seen at 20 h after injection and later, but there were differences early after infusion (0.5 h
after … Kulkarni HR, Baum RP. Patient selection for personalized peptide receptor radionuclide …
after … Kulkarni HR, Baum RP. Patient selection for personalized peptide receptor radionuclide …
Biogenesis and multifaceted roles of outer membrane vesicles from Gram-negative bacteria
HM Kulkarni, MV Jagannadham - Microbiology, 2014 - microbiologyresearch.org
Outer membrane vesicles (OMVs) released from Gram-negative bacteria consist of lipids,
proteins, lipopolysaccharides and other molecules. OMVs are associated with several …
proteins, lipopolysaccharides and other molecules. OMVs are associated with several …
[HTML][HTML] Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
…, TM O'Dorisio, RP Baum, HR Kulkarni… - … England Journal of …, 2017 - Mass Medical Soc
Background Patients with advanced midgut neuroendocrine tumors who have had disease
progression during first-line somatostatin analogue therapy have limited therapeutic options. …
progression during first-line somatostatin analogue therapy have limited therapeutic options. …
The Influence of CCL3L1 Gene-Containing Segmental Duplications on HIV-1/AIDS Susceptibility
E Gonzalez, H Kulkarni, H Bolivar, A Mangano… - Science, 2005 - science.org
Segmental duplications in the human genome are selectively enriched for genes involved in
immunity, although the phenotypic consequences for host defense are unknown. We show …
immunity, although the phenotypic consequences for host defense are unknown. We show …
German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients
…, M Essler, RP Baum, HR Kulkarni… - Journal of Nuclear …, 2017 - Soc Nuclear Med
177 Lu-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT)
of patients with metastatic castration-resistant prostate cancer (mCRPC). Initiated by the …
of patients with metastatic castration-resistant prostate cancer (mCRPC). Initiated by the …
68Ga-and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies
…, A Yildiz, S Beykan, HR Kulkarni… - Journal of Nuclear …, 2015 - Soc Nuclear Med
… Dynamic imaging was performed for 1.5 h after on-bed injection. Static images were recorded
at 1 h after injection with an acquisition time of 15 min. Images were reconstructed using 3-…
at 1 h after injection with an acquisition time of 15 min. Images were reconstructed using 3-…
177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy
RP Baum, HR Kulkarni, C Schuchardt… - Journal of Nuclear …, 2016 - Soc Nuclear Med
… HCl (amino acid solution) intravenously over 4 h, starting 30 min before radiopharmaceutical
… h after injection. SPECT/CT imaging was obtained between 45 and 118 h after injection. …
… h after injection. SPECT/CT imaging was obtained between 45 and 118 h after injection. …
HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels
…, R Dhanda, S Mummidi, H Kulkarni… - Proceedings of the …, 2002 - National Acad Sciences
Studies in humans and in experimental models of HIV-1 infection indicate an important role
for monocyte chemoattractant protein-1 (MCP-1; also known as CC chemokine ligand 2), a …
for monocyte chemoattractant protein-1 (MCP-1; also known as CC chemokine ligand 2), a …
Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection
…, PA Mudd, HJ Chun, JP Atkinson, HS Kulkarni - Science …, 2021 - science.org
Complement activation has been implicated in the pathogenesis of severe SARS-CoV-2
infection. However, it remains to be determined whether increased complement activation is a …
infection. However, it remains to be determined whether increased complement activation is a …